Can-Fite BioPharma Ltd. (CANF) Form 6-K — Jun 26, 2026

Can-Fite BioPharma announced that the Japan Patent Office has allowed a patent application covering the use of its drug candidate Namodenoson for inducing fat loss and treating obesity. This allowance strengthens the company's intellectual property portfolio in a major pharmaceutical market, adding to existing protections in the US, Canada, Australia, and Israel. The allowed patent covers A3 adenosine receptor agonists for treating obesity and related metabolic disorders, supporting the positioning of Namodenoson as an orally administered therapy. The company noted that the global obesity therapeutics market is expected to exceed $60 billion by 2030.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.